Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(6 years from now) | |
US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(6 years from now) | |
US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(7 years from now) | |
US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(7 years from now) | |
US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(7 years from now) | |
US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(7 years from now) | |
US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(7 years from now) | |
US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(7 years from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver
Dosage: TABLET;ORAL
117
United States
36
Japan
26
European Union
23
Israel
19
Canada
16
China
16
Taiwan
15
Korea, Republic of
11
Australia
9
Hong Kong
8
Brazil
7
Singapore
6
Malaysia
6
Denmark
6
Mexico
5
Spain
5
Russia
5
South Africa
4
India
3
Ukraine
3
Portugal
2
New Zealand
2
Chile
1
Poland
1
Morocco
1
EA
1
Cyprus
1
Peru
1
Costa Rica
1
Ecuador
1
Finland
1
Tunisia
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8741959 | FRESENIUS KABI USA | Paracetamol for parenteral administration |
Apr, 2030
(6 years from now) |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 28 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
4
European Union
3
United States
2
Poland
2
Spain
2
Denmark
1
China
1
Hong Kong
1
Brazil
1
Portugal
1
Japan
1
Australia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC
5
United States
5
European Union
2
Spain
2
China
1
Korea, Republic of
1
Russia
1
Hong Kong
1
Brazil
1
Canada
1
Taiwan
1
Singapore
1
Argentina
1
Japan
1
Australia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415009 | BOND | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jan 10, 2026 |
Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient
Market Authorisation Date: 10 January, 2023
Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older
Dosage: AEROSOL, METERED;INHALATION
26
United States
10
Japan
9
Taiwan
8
Lithuania
8
Hungary
7
Russia
7
Korea, Republic of
7
Australia
6
Spain
6
Hong Kong
6
Denmark
6
Poland
6
China
6
Argentina
6
Croatia
6
Portugal
6
Slovenia
6
European Union
5
Cyprus
4
Mexico
3
Brazil
3
Canada
3
Ukraine
3
San Marino
3
Israel
3
South Africa
2
Norway
2
Luxembourg
1
Philippines
1
ME
1
Netherlands
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US11559523 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(7 years from now) |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 10 October, 2014
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...
Dosage: CAPSULE;ORAL
11
United States
6
China
4
Spain
4
European Union
3
Poland
3
Croatia
2
Hong Kong
2
Denmark
2
RS
2
San Marino
2
Cyprus
2
Portugal
2
Slovenia
1
IB
1
Dominican Republic
1
Malaysia
1
AP
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
Japan
1
Nicaragua
1
New Zealand
1
Korea, Republic of
1
Guatemala
1
Peru
1
Israel
1
Chile
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Cuba
1
Costa Rica
1
Ecuador
1
South Africa
1
Colombia
1
Lithuania
1
Tunisia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) | |
US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 19, 2023 |
NCE-1 date: 2022-04-19
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
11
United States
6
China
4
Spain
4
European Union
3
Poland
3
Croatia
2
Hong Kong
2
Denmark
2
RS
2
San Marino
2
Cyprus
2
Portugal
2
Slovenia
1
IB
1
Dominican Republic
1
Malaysia
1
AP
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
Japan
1
Nicaragua
1
New Zealand
1
Korea, Republic of
1
Guatemala
1
Peru
1
Israel
1
Chile
1
Taiwan
1
Georgia
1
Mexico
1
Australia
1
Cuba
1
Costa Rica
1
Ecuador
1
South Africa
1
Colombia
1
Lithuania
1
Tunisia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9440922 | HOFFMANN-LA ROCHE | Tetracyclic compound |
Jun, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 6, 2024 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
6
United States
4
Japan
4
Hungary
4
European Union
3
Spain
3
Denmark
3
Poland
3
Croatia
3
Portugal
3
Lithuania
3
Slovenia
2
Russia
2
Norway
2
Taiwan
1
Hong Kong
1
Malaysia
1
RS
1
China
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Morocco
1
Argentina
1
New Zealand
1
Korea, Republic of
1
Cyprus
1
Peru
1
Israel
1
Chile
1
Mexico
1
Australia
1
Costa Rica
1
Ecuador
1
Netherlands
1
South Africa
1
Colombia
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Feb 25, 2028 |
New Chemical Entity Exclusivity (NCE) | Feb 25, 2026 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 2025-02-25
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients who have...
Dosage: SOLUTION;INTRAVENOUS
7
United States
6
Korea, Republic of
6
Australia
5
Japan
5
Israel
4
New Zealand
2
China
2
European Union
1
Spain
1
Turkey
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Croatia
1
Cyprus
1
Portugal
1
Lithuania
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10086080 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US10265404 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
US10821187 | JOURNEY | Compositions, gels and foams with rheology modulators and uses thereof |
Oct, 2030
(7 years from now) | |
US10213512 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US8992896 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US9675700 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US8865139 | JOURNEY | Topical tetracycline compositions |
Oct, 2030
(7 years from now) | |
US10137200 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) | |
US10517882 | JOURNEY | Method for healing of an infected acne lesion without scarring |
Oct, 2030
(7 years from now) | |
US8945516 | JOURNEY | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
Oct, 2030
(7 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
52
United States
5
IB
5
Canada
2
Israel
2
Australia
1
China
1
Brazil
1
South Africa
1
Mexico
1
United Kingdom
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11253478 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(6 years from now) | |
US9974746 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(6 years from now) | |
US10709713 | BAUDAX | Nanoparticulate meloxicam formulations |
May, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
20
United States
8
Japan
6
European Union
3
Spain
2
Canada
2
Denmark
2
Hungary
1
Germany
1
Austria
1
Taiwan
1
Australia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(6 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(7 years from now) | |
US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jun 9, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
17
United States
8
Australia
7
European Union
6
Korea, Republic of
6
United Kingdom
5
China
5
Japan
4
Brazil
4
Canada
4
Hungary
3
Spain
3
Denmark
3
Poland
3
Norway
3
New Zealand
3
Israel
3
Portugal
3
South Africa
2
Malaysia
2
Singapore
2
Cyprus
2
Peru
2
Mexico
2
Lithuania
1
Hong Kong
1
Dominican Republic
1
Turkey
1
RS
1
Russia
1
Ukraine
1
Morocco
1
Argentina
1
EA
1
ME
1
Croatia
1
Chile
1
Taiwan
1
Slovenia
1
Costa Rica
1
Colombia
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9132125 | KVK TECH INC | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(7 years from now) | |
US9549923 | KVK TECH INC | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof |
Jul, 2030
(7 years from now) | |
US8748413 | KVK TECH INC | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8828978 | KVK TECH INC | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Jul, 2030
(7 years from now) |
Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 February, 2018
Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: TABLET;ORAL
17
United States
5
Korea, Republic of
2
Israel
2
South Africa
2
European Union
1
Malaysia
1
China
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Japan
1
New Zealand
1
Chile
1
Mexico
1
Australia
1
Cuba
1
Costa Rica
1
Colombia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8865688 | VALEANT PHARMS INTL | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(6 years from now) |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
5
United States
1
New Zealand
1
China
1
Israel
1
Canada
1
South Africa
1
Ukraine
1
Chile
1
EA
1
Mexico
1
Japan
1
Australia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(6 years from now) |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
Market Authorisation Date: 08 November, 2013
Treatment: NA
Dosage: TABLET;ORAL
6
United States
4
Japan
3
Korea, Republic of
3
Portugal
2
Spain
2
European Union
1
Denmark
1
RS
1
Poland
1
Russia
1
China
1
Brazil
1
Canada
1
Ukraine
1
Argentina
1
Croatia
1
Cyprus
1
Mexico
1
Australia
1
Lithuania
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
21
United States
7
Japan
4
Canada
3
European Union
2
Spain
2
Argentina
2
New Zealand
2
Australia
1
Hong Kong
1
Denmark
1
RS
1
Poland
1
Croatia
1
Cyprus
1
Portugal
1
Taiwan
1
Lithuania
1
Saudi Arabia
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
21
United States
7
Japan
4
Canada
3
European Union
2
Spain
2
Argentina
2
New Zealand
2
Australia
1
Hong Kong
1
Denmark
1
RS
1
Poland
1
Croatia
1
Cyprus
1
Portugal
1
Taiwan
1
Lithuania
1
Saudi Arabia
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(6 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Mar 1, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 20 August, 2014
Treatment: NA
Dosage: POWDER;INHALATION
5
United States
5
United Kingdom
3
Japan
3
Korea, Republic of
2
Spain
2
Denmark
2
Poland
2
China
2
Brazil
2
Canada
2
Norway
2
New Zealand
2
Israel
2
Portugal
2
Australia
2
South Africa
2
Hungary
2
European Union
1
Malaysia
1
Argentina
1
Cyprus
1
Taiwan
1
Mexico
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8474447 | BOEHRINGER INGELHEIM | Inhaler device |
Jan, 2030
(6 years from now) |
Drugs and Companies using IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 27 November, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
2
European Union
1
United States
1
Poland
1
Germany
1
Spain
1
Canada
1
Japan
1
Denmark
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Apr 30, 2024 |
Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
8
United States
4
China
3
Israel
3
European Union
2
Hong Kong
2
Russia
2
Ukraine
2
New Zealand
2
Peru
2
Chile
2
Taiwan
2
Australia
2
Costa Rica
1
Uruguay
1
Spain
1
Dominican Republic
1
Malaysia
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Morocco
1
Argentina
1
Japan
1
ME
1
Nicaragua
1
Croatia
1
Honduras
1
Korea, Republic of
1
Guatemala
1
Cyprus
1
Portugal
1
Jordan
1
Mexico
1
Colombia
1
Lithuania
1
Tunisia
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(7 years from now) | |
US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(7 years from now) |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorus levels
Dosage: TABLET;ORAL
9
United States
9
Taiwan
3
Korea, Republic of
3
China
2
Russia
1
Israel
1
Canada
1
Brazil
1
Ukraine
1
Mexico
1
Australia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
New Patient Population (NPP) | Dec 20, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 2024-02-26
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
7
United States
4
Japan
4
Korea, Republic of
4
European Union
3
China
2
Spain
2
Russia
2
Brazil
2
Israel
1
Hong Kong
1
Malaysia
1
Turkey
1
Denmark
1
Poland
1
Canada
1
France
1
Cyprus
1
Portugal
1
Mexico
1
Australia
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(6 years from now) | |
US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(7 years from now) |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
7
United States
1
Korea, Republic of
1
China
1
Brazil
1
Canada
1
Taiwan
1
Argentina
1
Mexico
1
Japan
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9463161 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8808713 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8703806 | ASTRAZENECA | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8324266 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) |
Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
26
United States
10
Japan
9
Taiwan
8
Lithuania
8
Hungary
7
Russia
7
Korea, Republic of
7
Australia
6
Spain
6
Hong Kong
6
Denmark
6
Poland
6
China
6
Argentina
6
Croatia
6
Portugal
6
Slovenia
6
European Union
5
Cyprus
4
Mexico
3
Brazil
3
Canada
3
Ukraine
3
San Marino
3
Israel
3
South Africa
2
Norway
2
Luxembourg
1
Philippines
1
ME
1
Netherlands
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 2021-06-23
Market Authorisation Date: 23 June, 2017
Treatment: NA
Dosage: CAPSULE;ORAL
4
United States
2
China
2
Japan
1
Spain
1
Canada
1
Portugal
1
Taiwan
1
Argentina
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(6 years from now) |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: NA
Dosage: TABLET;ORAL
3
United States
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(6 years from now) | |
US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
New Indication (I) | Apr 8, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 2022-06-27
Market Authorisation Date: 27 June, 2018
Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the tre...
Dosage: CAPSULE;ORAL
18
United States
5
European Union
3
Spain
3
Denmark
3
Poland
3
China
3
EA
3
Japan
3
Croatia
3
Cyprus
3
Portugal
3
Lithuania
3
Slovenia
3
Hungary
2
Hong Kong
2
RS
2
Brazil
2
Canada
2
Singapore
2
ME
2
San Marino
2
Chile
2
Mexico
2
Australia
1
Uruguay
1
Austria
1
Dominican Republic
1
Malaysia
1
India
1
Ukraine
1
Morocco
1
Argentina
1
Norway
1
Nicaragua
1
Honduras
1
Korea, Republic of
1
New Zealand
1
Guatemala
1
Peru
1
Israel
1
Georgia
1
Jordan
1
Cuba
1
Costa Rica
1
Ecuador
1
Netherlands
1
South Africa
1
Colombia
1
Luxembourg
1
Tunisia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(6 years from now) | |
US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(7 years from now) |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: NA
Dosage: POWDER;INHALATION
5
United States
5
United Kingdom
3
Japan
3
Korea, Republic of
2
Spain
2
Denmark
2
Poland
2
China
2
Brazil
2
Canada
2
Norway
2
New Zealand
2
Israel
2
Portugal
2
Australia
2
South Africa
2
Hungary
2
European Union
1
Malaysia
1
Argentina
1
Cyprus
1
Taiwan
1
Mexico
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8188085 | SCYNEXIS | Antifungal agents |
Aug, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 1, 2026 |
New Indication (I) | Nov 30, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Jun 1, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 2030-06-01
Market Authorisation Date: 01 June, 2021
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)
Dosage: TABLET;ORAL
3
United States
2
China
1
Hong Kong
1
Canada
1
Japan
1
Australia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Combination (NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
26
United States
10
Japan
9
Taiwan
8
Lithuania
8
Hungary
7
Russia
7
Korea, Republic of
7
Australia
6
Spain
6
Hong Kong
6
Denmark
6
Poland
6
China
6
Argentina
6
Croatia
6
Portugal
6
Slovenia
6
European Union
5
Cyprus
4
Mexico
3
Brazil
3
Canada
3
Ukraine
3
San Marino
3
Israel
3
South Africa
2
Norway
2
Luxembourg
1
Philippines
1
ME
1
Netherlands
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(6 years from now) | |
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Nov 5, 2023 |
M (M) | May 9, 2025 |
Pediatric Exclusivity (PED) | Nov 28, 2023 |
Drugs and Companies using TICAGRELOR ingredient
Market Authorisation Date: 20 July, 2011
Treatment: NA
Dosage: TABLET;ORAL
3
United States
2
Malaysia
2
Russia
2
Japan
2
New Zealand
2
Australia
1
Uruguay
1
Spain
1
Philippines
1
Denmark
1
RS
1
Poland
1
China
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Argentina
1
Norway
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Chile
1
Israel
1
Portugal
1
Taiwan
1
Slovenia
1
Mexico
1
South Africa
1
Colombia
1
Lithuania
1
Saudi Arabia
1
Sweden
1
Hungary
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
Market Authorisation Date: 12 May, 2016
Treatment: NA
Dosage: TABLET;ORAL
3
European Union
2
Hong Kong
2
United States
2
China
1
Spain
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
EA
1
Japan
1
ME
1
Croatia
1
Korea, Republic of
1
San Marino
1
Cyprus
1
Israel
1
Portugal
1
Mexico
1
Australia
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(6 years from now) | |
US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(6 years from now) | |
US8998876 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(7 years from now) | |
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
3
European Union
2
United States
1
Germany
1
Taiwan
1
Switzerland
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to i...
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
8
United States
2
China
2
Japan
2
European Union
1
Spain
1
Denmark
1
Poland
1
Brazil
1
Canada
1
Singapore
1
EA
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Israel
1
Portugal
1
Mexico
1
Australia
1
Lithuania
1
Slovenia
1
Hungary